Serial No.10/579,160

Amendments to the Claims

Docket No. 13566.105023

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- (currently amended) A method of treating a human body having cancer comprising administering an effective therapeutic amount of ET-743 in combination with an effective therapeutic amount of 5-fluorouracil or a pro-drug thereof a 5-fluorouracil pro-drug.
- 2. (canceled)
- (currently amended) The method according to elaim 2 claim 1, wherein ET-743 is administered in combination with capecitabine.
- 4. (original) The method according to claim 3, wherein capecitabine and ET-743 are provided as separate medicaments for administration at different times.
- 5. (original) The method according to claim 4, wherein capecitabine is administered in a dose range between 1500 to $2500 \text{ mg/m}^2/\text{day}$.
- 6. (original) The method according to claim 4, wherein ET-743 is administered in a dose range between 0.75 and 1.4 mg/m².

- 7. (original) The method according to claim 5 or 6, wherein capecitabine is administered in a dosage of up to 2000 mg/m²/dav and ET-743 is administered in a dosage of up to 1.2 mg/m².
- 8. (original) The method according to claim 7, wherein capecitabine is administered in a dosage about 1600 mg/m²/day and ET-743 is administered in a dosage about 0.9 mg/m².
- 9. (original) The method according to claim 5 or 6, wherein capecitabine is orally administered.
- 10. (original) The method according to claim 9, wherein ET-743 is administered by intravenous injection.
- 11. (original) The method according to claim 10, wherein the infusion time for intravenous injection of ET-743 is up to 24 hours.
- (original) The method according to claim 11, wherein the infusion time for intravenous injection of ET-743 is about 3 hours for ET-743.
- 13. (original) The method according to claim 10, where the infusions of ET-743 are carried out at an interval of 1 to 6 weeks.
- 14. (original) The method according to claim 13, wherein the infusion of ET-743 is carried out once every 21 days.

15. (original) The method according to claim 14, wherein the infusion of ET-743 is carried out on day 1 and the administration of capecitabine from days 2 to 15, every 21 days.

16. (original) The method according to claim 15, wherein capecitabine is administered twicedaily.

17. (currently amended) A method according to any preceding claim claim 1, in which the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, vaginal cancer, colorectal cancer, gastric cancer, adenocarcinoma, mesothelioma, renal cancer, endometrial cancer and lung cancer.

18. (original) A method according to claim 17, in which the patient has a cancer selected from sarcoma, breast cancer, gastric cancer, vaginal cancer and adenocarcinoma.

19. (canceled)

20. (canceled)

21. (original) A medical kit for administering ET-743 in combination with capecitabine, comprising a supply of ET-743 in dosage units for at least one cycle, wherein each dosage unit contains the appropriate amount of ET-743 for the treatments and a pharmaceutically acceptable carrier, and printed instructions for administering ET-743 according to a dosing schedule.

- 22. (new) The method according to claim 5, wherein capecitabine is administered in a dosage of about $2000 \text{ mg/m}^2/\text{day}$.
- 23. (new) The method according to claim 5, wherein capecitabine is administered in a dosage of about 1600 mg/m²/day.
- 24. (new) The method according to claim 6, wherein ET-743 is administered in a dose range between 0.9 and 1.2 mg/m².
- 25. (new) The method according to claim 6, wherein ET-743 is administered in a dosage of about 0.9 mg/m².